National Pharmaceutical Pricing Authority notifies retail prices of 41 new drugs: Gireesh Babu, New Delhi Thursday, June 5, 2025, 08:00 Hrs [IST] The National Pharmaceutical Prici ...

Ahmedabad: Zydus Lifesciences Limited has announced that it has entered into a definitive agreement with Agenus Inc. to ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

Zydus also entered into a definitive agreement with Agenus Inc to acquire India and Sri Lanka commercial rights for its investigational Botensilimab (BOT) and Balstilimab (BAL), combination therapy.

Agenus will give Zydus an exclusive licence for the development and commercialisation of BOT and BAL in Sri Lanka and India.

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets ...

Zydus Lifesciences has received tentative approval from the US Food and Drug Administration to market Rifaximin Tablets in ...

I’m PCMag’s managing editor for consumer electronics content, overseeing an experienced team of reviewers and product testers. I’ve been covering tech for more than 22 years. Prior to PCMag ...

Also, would a combination of these drugs result in greater symptomatic relief and an improvement in peak urinary flow (Q max)? The first question has largely been answered by a 4-year trial with ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.